Cepheid, Novartis Partner to Bring Leukemia Test to US

Cepheid will receive $5 million in an upfront payment and $3 million in milestone payments over the next 12 months as part of the deal, while Novartis would have exclusive global distribution rights to the test upon its commercialization in the US.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.